Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.40), $0.02 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $3.07 million versus the consensus estimate of $1.24 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.